Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 1499 | 19.35 |
09:36 ET | 384 | 19.28 |
09:43 ET | 100 | 19.42 |
09:54 ET | 700 | 19.42 |
09:56 ET | 300 | 19.39 |
09:57 ET | 100 | 19.4 |
09:59 ET | 292 | 19.405 |
10:17 ET | 120 | 19.48 |
10:19 ET | 500 | 19.475 |
10:24 ET | 310 | 19.5 |
10:30 ET | 3150 | 19.5401 |
10:32 ET | 927 | 19.605 |
10:39 ET | 100 | 19.62 |
10:42 ET | 100 | 19.63 |
10:44 ET | 400 | 19.615 |
10:46 ET | 100 | 19.59 |
10:50 ET | 100 | 19.62 |
10:53 ET | 100 | 19.59 |
11:18 ET | 600 | 19.4916 |
11:20 ET | 300 | 19.46 |
11:22 ET | 200 | 19.43 |
11:24 ET | 100 | 19.41 |
11:26 ET | 417 | 19.45 |
11:38 ET | 341 | 19.45 |
11:40 ET | 100 | 19.46 |
11:51 ET | 300 | 19.42 |
11:54 ET | 500 | 19.41 |
11:58 ET | 1400 | 19.3416 |
12:00 ET | 100 | 19.32 |
12:05 ET | 816 | 19.34 |
12:09 ET | 200 | 19.31 |
12:12 ET | 420 | 19.3 |
12:18 ET | 200 | 19.32 |
12:21 ET | 100 | 19.33 |
12:32 ET | 206 | 19.31 |
12:38 ET | 3984 | 19.27 |
12:39 ET | 500 | 19.28 |
12:43 ET | 100 | 19.28 |
12:48 ET | 100 | 19.26 |
12:54 ET | 1100 | 19.24 |
12:57 ET | 100 | 19.24 |
01:01 ET | 663 | 19.23 |
01:06 ET | 900 | 19.2483 |
01:30 ET | 200 | 19.18 |
01:42 ET | 400 | 19.18 |
01:44 ET | 100 | 19.17 |
01:48 ET | 398 | 19.21 |
01:50 ET | 1000 | 19.2083 |
01:57 ET | 300 | 19.22 |
02:09 ET | 600 | 19.23 |
02:11 ET | 300 | 19.21 |
02:13 ET | 518 | 19.21 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.3B | 225.5x | --- |
Ginkgo Bioworks Holdings Inc | 1.2B | -1.2x | --- |
BioCryst Pharmaceuticals Inc | 1.3B | -5.9x | --- |
Dynavax Technologies Corp | 1.6B | 242.5x | --- |
Zai Lab Ltd | 1.9B | -5.6x | --- |
MannKind Corp | 1.3B | 199.5x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.33 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 225.5x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | 124.2x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.